A drug that has been sitting in medicine cabinets for over 70 years may have a surprising second act! A 70-year-old blood pressure drug, hydralazine, has revealed its molecular mechanism for fighting aggressive brain tumors. Scientists discovered it directly targets and shuts down a critical enzyme, ADO, which cancer cells rely on for survival. This breakthrough offers potential for developing more effective and selective cancer treatments.